A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
Clinical trial NCT00236444 · COMPLETED
Trial details
- NCT number
- NCT00236444
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2001-12-01
- Enrollment
- 375
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.